Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence
Article
[키워드] 95% confidence interval
Abbott
acute respiratory syndrome
Analysis
anti-SARS-CoV-2
anti-SARS-CoV-2 antibody
anti-SARS-CoV-2 IgG
Antigen
antigens
Architect
assays
CDC
collected
combinations
Concentration
Concordance
contributed
coronavirus
coronavirus disease
COVID-19
Elecsy
ELISA
enzyme-linked immunosorbent
evaluate
False positivity
first test
Frequency
IgG
IgG antibodies
immunoassay
immunoassays
Immunoglobulin
individual
investigated
low prevalence
nucleocapsid
nucleocapsid protein
pandemic
participant
Participants
performed
Period
positive
positive result
Prevalence
produced
proportion
quantified
Research
Result
Roche
SARS-CoV-2
SARS-CoV-2 antibody
SARS-CoV-2 IgG
SARS-CoV-2 IgG antibody
sequential test
sera
serological test
seropositive
specimen
Spike protein
subset
Support
target
tested
the SARS-CoV-2
The United States
Vaccine
vaccine availability
[DOI] 10.1128/msphere.00257-22 PMC 바로가기
[DOI] 10.1128/msphere.00257-22 PMC 바로가기